Silver Book Fact

Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.

Javitt J, Aiello L, Chiang Y, Greenfield S. Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform. Diabetes Care. 1994; 17(8): 909-17. http://care.diabetesjournals.org/cgi/content/abstract/17/8/909

Reference

Title
Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform
Publication
Diabetes Care
Publication Date
1994
Authors
Javitt J, Aiello L, Chiang Y, Greenfield S
Volume & Issue
Volume 17, Issue 8
Pages
909-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Family risk of glaucoma
    “‘Five of my nine brothers and sisters had glaucoma,’ says 81-year-old Jean R. who for 20 years has depended on eye drops to decrease pressure inside her eyes. Jean is…  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.